The findings of this NMA suggest favorable efficacy with SITT comprising FF/UMEC/VI versus long-acting β 2-agonist (LABA)/long-acting muscarinic antagonist, LABA/inhaled corticosteroid, multiple-inhaler triple therapy, and other SITTs. This network meta-analysis (NMA) investigated the comparative efficacy of SITT with fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI 100/62.5/25 µg) versus other triple and dual therapies in patients with COPD.įF/UMEC/VI showed significant improvement in trough forced expiratory volume in 1 s, and a significant reduction in combined annualized moderate and severe exacerbations, when compared with other therapies.Īs expected, there were some differences in the study design and inclusion/exclusion criteria of the trials included in the analysis, the estimates used as inputs (due to availability in the publications), and definitions of events between trials however, the similarity assumption held, confirming that the variability was not too high to prevent pooling of the data. Randomized controlled trials comparing different triple therapy regimens for the treatment of chronic obstructive pulmonary disease (COPD) are limited and there are no head-to-head trials for single-inhaler triple therapies (SITTs). Further analysis is required as additional evidence becomes available. The findings of this NMA suggest favorable efficacy with single-inhaler triple therapy comprising FF/UMEC/VI. ![]() FF/UMEC/VI also demonstrated improvements in mean SGRQ score versus other triple therapy comparators at 24 weeks, and a significant reduction in RMU compared with BUD/GLY/FOR (160/18/9.6). FF/UMEC/VI showed statistically significant improvements in annualized rate of combined moderate or severe exacerbations versus UMEC + FF/VI and BUD/GLY/FOR. At 24 weeks, the NMA was informed by five trials. FF/UMEC/VI demonstrated statistically significant improvements in annualized rate of combined moderate or severe exacerbations versus single-inhaler budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR). The NMA was informed by 17 trials reporting moderate or severe exacerbation endpoints. FF/UMEC/VI was statistically significantly more effective at increasing trough FEV 1 (based on change from baseline) than all triple comparators in the network apart from UMEC + FF/VI. The NMA was informed by five trials reporting FEV 1 at 24 weeks. Analyses were conducted at 24 weeks (primary endpoint), and 12 and 52 weeks (if feasible). Outcomes of interest included forced expiratory volume in 1 s (FEV 1), annualized rate of combined moderate and severe exacerbations, St George’s Respiratory Questionnaire (SGRQ) total score and SGRQ responders, transition dyspnea index focal score, and rescue medication use (RMU). The RCTs compared different ICS/LABA/LAMA combinations or an ICS/LABA/LAMA combination with any dual therapy (ICS/LABA or LAMA/LABA). This NMA was conducted on the basis of a systematic literature review (SLR), which identified RCTs in adults aged at least 40 years with COPD. This network meta-analysis (NMA) investigated the comparative efficacy of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus any triple (ICS/LABA/LAMA) combinations and dual therapies in patients with COPD. Randomized controlled trials (RCTs) comparing triple therapies (inhaled corticosteroid, long-acting β 2-agonist, and long-acting muscarinic antagonist ) for the treatment of chronic obstructive pulmonary disease (COPD) are limited.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |